Motley Fool Asset Management LLC Sells 93,201 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Motley Fool Asset Management LLC reduced its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 65.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 48,448 shares of the biopharmaceutical company's stock after selling 93,201 shares during the period. Motley Fool Asset Management LLC owned approximately 0.05% of Ultragenyx Pharmaceutical worth $2,038,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in RARE. Van ECK Associates Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after acquiring an additional 294 shares during the period. Smartleaf Asset Management LLC grew its position in Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 493 shares in the last quarter. M&T Bank Corp raised its stake in shares of Ultragenyx Pharmaceutical by 8.1% during the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock valued at $388,000 after purchasing an additional 525 shares during the period. Finally, Arizona State Retirement System boosted its stake in shares of Ultragenyx Pharmaceutical by 2.4% in the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company's stock valued at $1,011,000 after purchasing an additional 568 shares during the period. Hedge funds and other institutional investors own 97.67% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on RARE shares. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Wedbush reiterated a "neutral" rating and issued a $48.00 target price (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, Wells Fargo & Company lifted their price target on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares of the company's stock, valued at $4,289,227.60. This represents a 1.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock worth $5,256,268 over the last 90 days. Insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Up 9.2 %

Shares of RARE stock traded up $2.85 during trading on Wednesday, reaching $33.91. The company's stock had a trading volume of 2,063,234 shares, compared to its average volume of 804,512. The business has a fifty day moving average price of $39.78 and a 200-day moving average price of $45.21. The company has a market cap of $3.18 billion, a price-to-earnings ratio of -5.35 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a one year low of $29.59 and a one year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. Research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.